WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 82'7301 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 52'0631 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 7'997  7'915  7'831  7'743  7'653  7'166  6'674  6'304 
Births 82  81  80  78  77  76  81  73 
Surviving infants 82  81  79  78  77  76  80  72 
Pop. less than 5 years 400  393  384  378  372  401  385  356 
Pop. less than 15 years 1'189  1'184  1'179  1'182  1'186  1'250  1'137  1'261 
Female 15-49 years 1'916  1'907  1'896  1'885  1'871  1'766  1'719  1'587 

Number of reported case

(Click for retrospective incidence data for Switzerland)
Diphtheria
Japanese encephalitis
Measles 61  621  77  958  2'022  1'990 
Mumps 140  600  900 
Pertussis 4'700  5'900  3'700 
Polio*
Rubella 10  12  35  12 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Switzerland)
Vaccine year result method % card seen                                                
BCG         
DTP1          95  95  95 
DTP3          95  95  96  95  95  88  90 
HepB_BD         
HepB3         
Hib3          95  95  94  93  95  86 
JapEnc         
MCV          92  92  90  87  90  81  90 
MCV2          83  82  81  71  71 
PCV1          79 
PCV3          74 
Pol3          96  95  95  95  95  92  98 
Rota1         
Rota_last         
Rubella1          91  91  90  86  86 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Switzerland)
DTP1 95  95  98  95  95  95  96 
DTP3 95  95  96  95  95  88  90 
HepB3
Hib3 95  95  94  95  95  86 
MCV 92  92  92  90  90  81  90 
PCV3 74  74  74 
Pol3 96  95  95  95  95  92  98 
Rota_last

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibIPV 2, 4, 6, 15-24 months; Yes
DTaPIPV 4-7 years; Yes
HPV 11-14 years; +6 months; Yes
HepB 11-15 years; +6 months; Yes
Influenza >= 65 years;
MMR 12, 15-24 months; Yes
MenC_conj 12-15 months; 11-15 years; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps >= 65 years;
Td 11-15 years; +10 years; Yes
Varicella 11 years; +1 month; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2012-2015             
Nº of districts with microplans that include activities to raise immunization coverage number              

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number   26  26  26  26  26  26 
Nº districts with DTP3 coverage >=80% number       22  16   
% of districts with DTP3 coverage >=80% From 0 to 100%         85  62   
Nº districts with measles (MCV1) coverage >=95% number        
% of districts with MCV1 coverage >=95% From 0 to 100%          

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes         

Finance

Percentage of routine vaccines funded by Government From 0 to 100%

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.